Voxel

Voxel S.A. Reports Strong Financial Performance in 2023 with Strategic Expansions and Innovations

Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has announced its financial results for 2023, showcasing significant growth and strategic advancements. The company reported a revenue of over PLN 454 million, marking a 59% increase in operating profit to PLN 108 million compared to the previous year. EBITDA rose to PLN 147 million, while net profit exceeded PLN 75 million. The diagnostic imaging segment remained the strongest contributor to the company's performance, supported by the expansion of its network to 68 laboratories nationwide.

In 2023, Voxel S.A. focused on modernizing its medical equipment and standardizing diagnostic protocols, which led to an increase in the number of procedures performed. The company also opened a new MRI laboratory in a building constructed using Cross-Laminated Timber (CLT) technology, enabling rapid deployment and participation in a National Health Fund (NFZ) tender for MRI services. Additionally, Voxel S.A. received approval for a new radiopharmaceutical marked with Ga-68 for PET-CT procedures and expanded its nuclear cardiology services by installing a second gamma camera dedicated to cardiac SPECT studies in Katowice.

Voxel S.A. also emphasized its commitment to innovation and sustainability by launching a Digital Transformation Project, which includes a "paperless" policy and the implementation of electronic medical documentation. The company plans to continue its growth trajectory in 2024, with the opening of a new MRI and CT facility in Varso Place, Warsaw, in the second quarter.

In terms of corporate restructuring, Voxel S.A. sold its 100% stake in VITO-MED sp. z o.o. due to a lack of significant synergies with its core business. The company retained the diagnostic laboratory segment of VITO-MED, which focuses on SARS-CoV-2 testing, and integrated it into a newly established subsidiary, Serpens sp. z o.o.

Voxel S.A. also highlighted its efforts to address the shortage of specialized medical personnel by offering training programs in radiology, diagnostic imaging, and nuclear medicine. In 2023, 22 doctors participated in these specialization programs.

Relevance to Voxel S.A.: The article highlights Voxel S.A.'s robust financial performance, strategic expansions, and commitment to innovation, aligning with its profile as a leader in diagnostic imaging and nuclear medicine services in Poland.

Voxel S.A. Reports Strong Financial Performance in H1 2024 Amid Strategic Investments and Expansion

Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported robust financial results for the first half of 2024, showcasing significant growth in revenue and profitability. The company achieved a consolidated revenue of PLN 232.6 million, marking a 28.8% increase compared to the same period in 2023. Net profit from continuing operations rose to PLN 42.5 million, a 25.3% increase year-on-year. The company also reported an EBITDA of PLN 79.6 million, reflecting a 21.1% growth compared to H1 2023.

Key drivers of this growth include increased diagnostic imaging volumes, higher sales of radiopharmaceuticals, and the expansion of its IT and infrastructure solutions through its subsidiary Alteris S.A. The company also made strategic investments in new diagnostic equipment and facilities, with capital expenditures amounting to PLN 40.2 million during the period. Additionally, Voxel S.A. finalized the acquisition of a 21.87% stake in Dicella sp. z o.o., a provider of IT services for medical research, further strengthening its position in healthcare IT solutions.

Despite these achievements, Voxel S.A. faced challenges, including a significant increase in operational costs due to higher wages for medical staff and increased expenses for materials and services. The company also reported a loss of PLN 5.1 million from the sale and disposal of medical equipment, which impacted its overall financial performance.

In a post-balance sheet event, Voxel S.A. acquired a controlling 51% stake in Radpoint sp. z o.o., transitioning the company into a subsidiary. This move is expected to enhance Voxel's capabilities in providing advanced radiology and IT solutions. Additionally, the company addressed tax liabilities from previous years, paying a total of PLN 6.8 million in taxes and penalties following a tax audit.

Relevance to Voxel S.A. Business Profile

This article highlights Voxel S.A.'s strong financial performance, strategic investments, and expansion efforts, which align with its core business of providing diagnostic imaging, nuclear medicine services, and healthcare IT solutions. These developments underscore the company's commitment to growth and innovation in the healthcare sector.

Voxel S.A. Reports Strong Financial Growth in 2024 Amid Strategic Innovations

Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported robust financial results for 2024, showcasing significant growth and strategic advancements. The company achieved revenues of nearly PLN 508 million, marking a 17% year-over-year increase. The operating profit rose to PLN 119 million, a 5% growth compared to the previous year, while EBITDA reached PLN 167 million, and net profit climbed to nearly PLN 98 million.

Key milestones for Voxel in 2024 included the signing of a Memorandum of Understanding (MOU) with GE Healthcare, positioning the company as a producer of next-generation PET radioisotopes for advanced diagnostics in Alzheimer's disease, cardiac perfusion studies, and oncology. Additionally, Voxel partnered with ABX to introduce Radelumin, an innovative diagnostic product for prostate cancer, which offers higher specificity and sensitivity compared to existing radioisotopes.

The company also expanded its operations by opening a state-of-the-art diagnostic center at Varso Place in Warsaw, offering cutting-edge CT and MRI technologies. Furthermore, Voxel invested in artificial intelligence (AI) solutions to enhance MRI diagnostics, improve efficiency, and optimize patient care. The company also continued its efforts to digitize patient services and implemented cloud-based technologies to streamline diagnostic processes.

Voxel's commitment to research and development was evident in its investments in a new radioisotope production facility and clinical research center, further solidifying its leadership in theranostic technologies. These advancements aim to integrate diagnostics and therapy, opening new avenues for treating cancer and other severe diseases.

Despite its achievements, Voxel faced challenges, including increased operational costs due to higher wages for medical personnel and rising energy prices. The company also addressed tax-related issues, including a dispute over withholding tax payments, which it resolved by making payments while pursuing reimbursement claims.

Voxel's strategic focus on innovation, expansion, and operational efficiency has positioned it as a leader in Poland's diagnostic imaging and nuclear medicine sectors. The company's financial performance and technological advancements underscore its commitment to delivering cutting-edge healthcare solutions.

Relevance to Voxel S.A.: This article highlights Voxel S.A.'s financial growth, strategic partnerships, and technological advancements, which align with its core business of providing innovative diagnostic imaging and nuclear medicine services across Poland.

Voxel S.A. Reports Robust Financial Growth and Strategic Expansion in 2024

Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has announced strong financial results for the fiscal year ending December 31, 2024. The Group reported consolidated sales revenues of nearly PLN 508 million, marking a significant increase from PLN 424 million in 2023. Operating profit reached PLN 119 million, up 5% year-on-year, while EBITDA climbed to PLN 167 million. Net profit for the year stood at almost PLN 98 million.

Key business developments in 2024 included the signing of a Memorandum of Understanding with GE Healthcare, positioning Voxel as a producer of next-generation PET radiopharmaceuticals for advanced diagnostics in Alzheimer’s disease, cardiac perfusion, and oncology (FAPI). Additionally, Voxel entered into an agreement with ABX to introduce Radelumin, an innovative [18F]PSMA-1007-based radiopharmaceutical for prostate cancer diagnostics, offering higher specificity and sensitivity than previous agents.

The Group continued to invest in theranostic technologies, expanding its PET diagnostics portfolio and establishing a new radiopharmaceutical production facility and clinical research center. These initiatives reinforce Voxel’s leadership in combining diagnostics and therapy for cancer and other serious diseases.

Voxel also advanced its digital transformation, implementing artificial intelligence (AI) algorithms in MRI diagnostics to increase throughput, enhance quality, and streamline workflows. The company launched a new diagnostic center at Varso Place in Warsaw, offering state-of-the-art cardiac CT and MRI services. Cloud-based technologies were deployed to optimize diagnostic processes and support scalable growth across Voxel’s imaging network.

In terms of corporate structure, Voxel acquired a controlling stake (51%) in Radpoint sp. z o.o., further strengthening its IT and infrastructure segment. The Group maintained a healthy financial position, with total assets rising to PLN 639 million and equity reaching PLN 367 million. A dividend of PLN 2.78 per share was distributed to shareholders in December 2024.

The annual consolidated financial statements received an unqualified opinion from the independent auditor, confirming compliance with International Financial Reporting Standards (IFRS) and Polish regulations. No significant post-balance sheet events were reported.

Relevance: This article is highly relevant to Voxel S.A.’s business profile as it highlights the company’s financial strength, strategic partnerships, technological innovation, and expansion in both diagnostics and healthcare IT, underscoring its position as a market leader in Poland’s medical imaging sector.

Voxel S.A. Reports Strong Financial Growth in Q1 2025 Amid Strategic Investments

Warsaw, Poland – May 28, 2025: Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported robust financial performance for the first quarter of 2025, driven by increased revenues and strategic investments in infrastructure and technology. The company achieved a 45% year-on-year increase in sales revenue, reaching PLN 157.8 million, compared to PLN 108.6 million in Q1 2024. Net profit rose to PLN 24.7 million, a 26% increase from the previous year. EBITDA margin for the quarter stood at an impressive 45%, reflecting operational efficiency across its core business segments: diagnostics, therapy, and IT & infrastructure.

Voxel S.A. continued its strategic expansion by investing PLN 33.1 million in new medical equipment and infrastructure, including the development of new diagnostic laboratories and the acquisition of advanced imaging technologies. The company also reported significant progress in its IT segment, with Alteris S.A. and Radpoint contributing to the growth through healthcare IT solutions and turnkey imaging projects. Additionally, Voxel S.A. maintained its focus on innovation, with ongoing R&D projects in radio-pharmaceuticals and AI-driven diagnostic tools.

Despite the positive financial results, the company faced challenges, including increased costs for materials, energy, and personnel due to the expansion of operations and salary adjustments for medical staff. Furthermore, Voxel S.A. addressed a tax dispute related to withholding tax on dividends paid to its Luxembourg-based parent company, Voxel International S.a.r.l., by making payments for prior years while pursuing a refund for overpaid taxes.

In terms of financing, the company reduced its debt obligations by repaying loans and bonds while increasing its leasing commitments to support its capital investments. Voxel S.A. also expanded its stake in Dicella sp. z o.o., a company specializing in innovative solutions, by acquiring additional shares in May 2025.

Relevance to Voxel S.A. Business Profile

This article highlights Voxel S.A.'s strong financial performance and strategic investments, which align with its core business of providing advanced diagnostic imaging, nuclear medicine, and healthcare IT solutions. The company's focus on innovation and infrastructure development underscores its commitment to maintaining its leadership in the Polish healthcare sector.

Voxel S.A. Reports Strong Financial Performance in H1 2025 Amid Strategic Expansion

Kraków, Poland – August 28, 2025: Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported robust financial results for the first half of 2025, showcasing significant growth in revenue and profitability. The company achieved a consolidated revenue of PLN 285.19 million, marking a 22.6% increase compared to the same period in 2024. Net profit attributable to shareholders of the parent company rose to PLN 46.14 million, a 10.4% increase year-over-year. The EBITDA margin for the diagnostics segment reached an impressive 44%, while the therapy segment achieved a 54% margin.

Voxel S.A. also announced key strategic developments, including the acquisition of 100% shares in PRO-SCAN sp. z o.o., a medical diagnostics company in Malbork, for PLN 7.98 million. This acquisition aligns with Voxel's strategy to expand its diagnostic imaging network and increase the number of conducted examinations. Additionally, the company secured a significant increase in its credit limit with BNP Paribas Bank Polska S.A., raising the limit from PLN 22 million to PLN 51 million, with an extended repayment period until July 2027. The funds will be used to refinance existing obligations and support operational growth.

Despite these achievements, Voxel S.A. faced challenges, including a decrease in cash and cash equivalents to PLN 8.01 million as of June 30, 2025, compared to PLN 52.91 million at the end of 2024. The company also reported higher costs related to leasing agreements and investments in new diagnostic equipment and facilities. Furthermore, Voxel S.A. is pursuing the recovery of over PLN 7 million in overpaid withholding tax for the years 2020-2022, following a dispute with Polish tax authorities.

Relevance to Voxel S.A.: The article highlights Voxel S.A.'s financial growth, strategic acquisitions, and operational expansion, which align with its core business of providing advanced diagnostic imaging and healthcare IT solutions across Poland.

Voxel S.A. Reports Strong Financial Performance and Strategic Expansion in Q3 2025

November 27, 2025 – Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported robust financial results for the first nine months of 2025, showcasing significant growth in revenue and net profit. The company achieved a 16.6% year-on-year increase in revenue, reaching PLN 428.15 million, compared to PLN 367.10 million in the same period of 2024. Net profit from continuing operations rose to PLN 74.74 million, a 10% increase from PLN 67.93 million in the previous year. The EBITDA margin for the diagnostics segment stood at an impressive 45%, reflecting the company's operational efficiency and market leadership.

Voxel S.A. also continued its strategic expansion, acquiring 100% of shares in SUPRAMED Konin sp. z o.o., a company specializing in MRI diagnostics funded by the National Health Fund (NFZ). This acquisition aligns with Voxel's strategy to expand its diagnostic imaging network and increase the number of diagnostic procedures performed. Additionally, the company secured a higher credit limit of PLN 70 million from BNP Paribas Bank Polska S.A. to support its growth initiatives, including the refinancing of obligations and funding for new acquisitions.

Despite the positive financial performance, Voxel S.A. faced challenges, including increased costs related to leasing, personnel, and operational expansion. The company also reported a decrease in cash and cash equivalents, which stood at PLN 20.36 million as of September 30, 2025, compared to PLN 52.91 million at the end of 2024. However, these challenges were offset by strategic investments and operational growth.

Voxel S.A. also announced the successful completion of its obligations related to the redemption of its Series M bonds, which were fully repaid by June 2025. The company continues to focus on its core business areas, including diagnostic imaging, radiopharmaceutical production, and healthcare IT solutions, while maintaining strong partnerships with the NFZ and other healthcare providers.

Relevance to Voxel S.A.: This article highlights Voxel S.A.'s financial growth, strategic acquisitions, and operational expansion, which align with its business profile as a leader in diagnostic imaging, nuclear medicine, and healthcare IT solutions in Poland.

Voxel S.A. Reports Strong Financial Performance in Q1 2026 Amid Strategic Expansion

Warsaw, Poland – May 28, 2026: Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported robust financial results for the first quarter of 2026, showcasing significant growth in revenue and profitability. The company achieved a consolidated revenue of PLN 157.2 million, with a net profit of PLN 32.4 million, marking a 31.5% increase in net profit compared to the same period in 2025. The Group's EBITDA margin also improved to 36% from 29% in Q1 2025, reflecting operational efficiency and increased demand for its diagnostic and therapeutic services.

Voxel S.A. attributed its growth to the expansion of its diagnostic imaging services, including CT, MRI, and PET-CT, as well as the integration of newly acquired subsidiaries such as "Pro-Scan" sp. z o.o. and Supramed Konin sp. z o.o. The company also reported increased revenues from its IT and infrastructure segment, driven by higher demand for healthcare IT systems and turnkey imaging solutions. Additionally, Voxel S.A. has continued its investment in new diagnostic laboratories and medical equipment, with capital expenditures reaching PLN 29.3 million in Q1 2026.

However, the company faced challenges with the National Health Fund (NFZ) altering the reimbursement model for CT and MRI scans performed beyond contractual limits, reducing funding to 50% of the potential revenue. Despite this, Voxel S.A. remains optimistic about its growth trajectory, supported by its strategic focus on expanding its service offerings and optimizing operations through mergers and acquisitions.

In a post-balance sheet event, Voxel S.A. announced a plan to merge with its subsidiaries "Pro-Scan" sp. z o.o. and Supramed Konin sp. z o.o., aiming to streamline operations and achieve cost efficiencies. This move aligns with the company's long-term strategy to consolidate its diagnostic services under a unified structure.

Relevance to Voxel S.A.: The article highlights Voxel S.A.'s financial growth, strategic acquisitions, and operational expansion, which align with its core business of providing advanced diagnostic imaging, nuclear medicine services, and healthcare IT solutions across Poland.

Voxel S.A. Reports Strong Financial Growth and Strategic Expansion in 2025

Voxel S.A., a leading provider of diagnostic imaging and nuclear medicine services in Poland, has reported a robust financial performance for the fiscal year 2025. The company achieved a 15% year-on-year increase in revenue, reaching PLN 583.8 million, and a 12% rise in operating profit to PLN 132.9 million. The EBITDA margin stood at 32%, reflecting a 13% growth compared to the previous year. Voxel also recorded a net profit of over PLN 100 million, marking a 3% increase from 2024.

Key drivers of this growth include the expansion of its diagnostic network through the acquisition of Pro-Scan Sp. z o.o. in Malbork and Supramed Konin Sp. z o.o. in Konin, as well as the opening of new diagnostic centers in Warsaw, Wadowice, and Jaworzno. The company also introduced advanced diagnostic procedures, such as PSMA-based prostate cancer diagnostics, and expanded its radioisotope production capabilities with the development of a new production facility in Katowice. Additionally, Voxel continued to integrate artificial intelligence (AI) and cloud-based technologies to enhance diagnostic efficiency and patient care.

Despite these achievements, Voxel faced challenges, including increased operational costs due to higher energy prices and staff wages, as well as delays in reimbursement for over-limit procedures from the National Health Fund (NFZ). The company also reported a rise in long-term financial liabilities, primarily due to investments in new equipment and facilities.

Voxel's strategic focus for 2026 includes further expansion of its diagnostic and therapeutic services, increased production of radioisotopes, and leveraging synergies within its group companies, including IT and infrastructure solutions provided by Alteris and Radpoint. The company aims to maintain its leadership in the diagnostic imaging sector while exploring new opportunities in oncology and teranostics.

Relevance to Voxel S.A.: This article highlights Voxel S.A.'s financial performance, strategic acquisitions, and technological advancements, which align with its core business of providing cutting-edge diagnostic imaging and nuclear medicine services across Poland.